Literature DB >> 25830382

Plk1 phosphorylation of IRS2 prevents premature mitotic exit via AKT inactivation.

Long Chen1, Zhiguo Li1, Nihal Ahmad2, Xiaoqi Liu1.   

Abstract

Insulin receptor substrate (IRS) proteins play important roles by acting as a platform in transducing signals from transmembrane receptors upon growth factor stimulation. Although tyrosine phosphorylation on IRS proteins plays critical roles in signal transduction, phosphorylation of IRS proteins on serine/threonine residues is believed to play various regulatory roles in IRS protein function. However, studies of serine/threonine phosphorylation of IRS proteins are very limited, especially for insulin receptor substrate 2 (IRS2), one member of the IRS protein family. In this study, we identify Polo-like kinase 1 (Plk1) as the responsible kinase for phosphorylation of IRS2 on two serine residues, Ser 556 and Ser 1098. Phosphorylation of IRS2 at these two serine residues by Plk1 prevents the activation of the PI3K pathway upon growth factor stimulation by inhibiting the binding between IRS2 and the PI3K pathway components and increasing the level of IRS2 protein degradation. Significantly, we show that IRS2 phosphorylation is cell cycle-regulated and that Plk1 phosphorylation of IRS2 prevents premature mitotic exit via AKT inactivation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25830382      PMCID: PMC4950874          DOI: 10.1021/acs.biochem.5b00016

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  30 in total

Review 1.  The insulin signalling pathway.

Authors:  Jose M Lizcano; Dario R Alessi
Journal:  Curr Biol       Date:  2002-04-02       Impact factor: 10.834

Review 2.  Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC.

Authors:  René H Medema; Chia-Chi Lin; James Chih-Hsin Yang
Journal:  Clin Cancer Res       Date:  2011-10-15       Impact factor: 12.531

3.  Insulin-induced serine phosphorylation of IRS-2 via ERK1/2 and mTOR: studies on the function of Ser675 and Ser907.

Authors:  Louise Fritsche; Sabine S Neukamm; Rainer Lehmann; Elisabeth Kremmer; Anita M Hennige; Andrea Hunder-Gugel; Martin Schenk; Hans-Ulrich Häring; Erwin D Schleicher; Cora Weigert
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-11-23       Impact factor: 4.310

4.  Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state.

Authors:  Zhiguo Li; Jie Li; Pengpeng Bi; Ying Lu; Grant Burcham; Bennett D Elzey; Timothy Ratliff; Stephen F Konieczny; Nihal Ahmad; Shihuan Kuang; Xiaoqi Liu
Journal:  Mol Cell Biol       Date:  2014-07-21       Impact factor: 4.272

Review 5.  Positive and negative regulation of insulin signaling through IRS-1 phosphorylation.

Authors:  Philippe Gual; Yannick Le Marchand-Brustel; Jean-François Tanti
Journal:  Biochimie       Date:  2005-01       Impact factor: 4.079

6.  Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells.

Authors:  Isabelle Briaud; Lorna M Dickson; Melissa K Lingohr; Jill F McCuaig; John C Lawrence; Christopher J Rhodes
Journal:  J Biol Chem       Date:  2004-11-09       Impact factor: 5.157

7.  The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.

Authors:  Péter Lénárt; Mark Petronczki; Martin Steegmaier; Barbara Di Fiore; Jesse J Lipp; Matthias Hoffmann; Wolfgang J Rettig; Norbert Kraut; Jan-Michael Peters
Journal:  Curr Biol       Date:  2007-02-08       Impact factor: 10.834

Review 8.  PTEN and the PI3-kinase pathway in cancer.

Authors:  Nader Chalhoub; Suzanne J Baker
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

Review 9.  Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2.

Authors:  K D Copps; M F White
Journal:  Diabetologia       Date:  2012-08-08       Impact factor: 10.122

Review 10.  From Plk1 to Plk5: functional evolution of polo-like kinases.

Authors:  Guillermo de Cárcer; Gerard Manning; Marcos Malumbres
Journal:  Cell Cycle       Date:  2011-07-15       Impact factor: 4.534

View more
  7 in total

1.  Plk1-Mediated Phosphorylation of TSC1 Enhances the Efficacy of Rapamycin.

Authors:  Zhiguo Li; Yifan Kong; Longzhen Song; Qian Luo; Jinghui Liu; Chen Shao; Xianzeng Hou; Xiaoqi Liu
Journal:  Cancer Res       Date:  2018-03-20       Impact factor: 12.701

2.  Functional Effects of AKT3 on Aurora Kinase Inhibitor-induced Aneuploidy.

Authors:  Kohji Noguchi; Keita Hongama; Shiori Hariki; Yuma Nonomiya; Kazuhiro Katayama; Yoshikazu Sugimoto
Journal:  J Biol Chem       Date:  2016-12-27       Impact factor: 5.157

3.  The Insulin Receptor Adaptor IRS2 is an APC/C Substrate That Promotes Cell Cycle Protein Expression and a Robust Spindle Assembly Checkpoint.

Authors:  Sandhya Manohar; Qing Yu; Steven P Gygi; Randall W King
Journal:  Mol Cell Proteomics       Date:  2020-06-18       Impact factor: 5.911

Review 4.  Regulatory functional territory of PLK-1 and their substrates beyond mitosis.

Authors:  Shiv Kumar; Garima Sharma; Chiranjib Chakraborty; Ashish Ranjan Sharma; Jaebong Kim
Journal:  Oncotarget       Date:  2017-06-06

5.  Loss of MyoD Promotes Fate Transdifferentiation of Myoblasts Into Brown Adipocytes.

Authors:  Chao Wang; Weiyi Liu; Yaohui Nie; Mulan Qaher; Hannah Elizabeth Horton; Feng Yue; Atsushi Asakura; Shihuan Kuang
Journal:  EBioMedicine       Date:  2017-01-13       Impact factor: 8.143

6.  Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.

Authors:  Yonghuan Mao; Ling Xi; Quan Li; Zeling Cai; Yimei Lai; Xinhua Zhang; Chunzhao Yu
Journal:  Oncol Rep       Date:  2016-05-18       Impact factor: 3.906

7.  Combination of PI3K/Akt Pathway Inhibition and Plk1 Depletion Can Enhance Chemosensitivity to Gemcitabine in Pancreatic Carcinoma.

Authors:  Yonghuan Mao; Ling Xi; Quan Li; Sheng Wang; Zeling Cai; Xinhua Zhang; Chunzhao Yu
Journal:  Transl Oncol       Date:  2018-05-10       Impact factor: 4.243

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.